Information Provided By:
Fly News Breaks for October 3, 2019
HRTX
Oct 3, 2019 | 06:37 EDT
JMP Securities analyst Liisa Bayko lowered her price target on Heron Therapeutics to $32 but kept her Outperform rating after its topline Phase 3b results for HTX-011 indicating that 75% of patients did not require opioids to manage their postoperative pain through 72 hours. The analyst notes that based on the FDA guidance to this point, she does not expect the agency to grant HTX-011 an "opioid sparing label", but she sees the "positive" results of the study supporting the company's case with the agency ahead of its PDUFA date in March.
News For HRTX From the Last 2 Days
There are no results for your query HRTX